February 14, 2025 - IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company developing innovative gamma-delta T cell therapies, yesterday presented ...

Among adults with relapsed or refractory indolent B-cell non-Hodgkin lymphoma, the phase 2 TRANSCEND FL trial met its primary ...

PRINCETON, N.J., Feb. 13, 2025 (GLOBE NEWSWIRE) -- Sonnet BioTherapeutics Holdings, Inc. (the "Company” or "Sonnet”) (NASDAQ: SONN), a clinical-stage company developing targeted immunotherapeutic ...

During a Case-Based Roundtable® event, Muhammad Umair Mushtaq, MD, discussed managing long-term toxicity concerns related to ...

CAR T-cell therapy for cancer leads to similar safety and cancer outcomes in patients with and without preexisting autoimmune ...

All treated AML patients in both the original and expansion cohorts through January 17, 2025 remain in complete remission. The original cohort of AML patients has reached a median CR of 23.3 months, ...

(AML) patients across both original and expansion cohorts remain in complete remission (CR), with a median follow-up of 20.1 months AML patients treated demonstrated one-year ...

CARsgen Therapeutics Holdings Limited (Stock Code: 2171), a company focused on innovative CAR T-cell therapies for the treatment of hematologic malignancies and solid tumors, announces that the first ...

CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on innovative CAR T-cell therapies for the ...

The cost — more than US$ 450,000 per treatment — limits accessibility, as does the complicatedness of their manufacture. Severe side effects like cytokine release syndrome (CRS) and neurotoxicity are ...

Inc. (Nasdaq: TSVT) today provided full-year Abecma® (idecabtagene vicleucel; ide-cel) sales results for 2024, in partnership with Brist ...